Cargando…
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
BACKGROUND AND OBJECTIVE: Pirfenidone is an oral antifibrotic agent that is approved in several countries for the treatment of idiopathic pulmonary fibrosis (IPF). We performed a comprehensive analysis of safety across four clinical trials evaluating pirfenidone in patients with IPF. METHODS: All pa...
Autores principales: | Valeyre, Dominique, Albera, Carlo, Bradford, Williamson Z, Costabel, Ulrich, King, Talmadge E, Leff, Jonathan A, Noble, Paul W, Sahn, Steven A, du Bois, Roland M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230393/ https://www.ncbi.nlm.nih.gov/pubmed/24836849 http://dx.doi.org/10.1111/resp.12297 |
Ejemplares similares
-
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
por: Noble, Paul W., et al.
Publicado: (2016) -
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016) -
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2016) -
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019) -
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)